Ipsen

Ipsen
Company type	Public
Traded as	Euronext Paris: IPN ; CAC Mid 60 Component
ISIN	FR0010259150
Industry	Pharmaceutical
Founded	1929
Founder	Henri Beaufour
Headquarters	Boulogne-Billancourt, France
Key people	Marc de Garidel (Non-executive Chairman) ; David Loew (Chief Executive Officer)
Products	List of medicines
Revenue	€3.128 billion(2023)
Operating income	€1.001 billion(2023)
Net income	€647 million(2023)
Number of employees	5,700
Website	www.ipsen.com
	Footnotes / references;

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.^[2]^[3]

Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005)^[4]^,.^[5] The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.^[6]

^ ^a ^b ^c ^d ^e "FY 2023 results" (PDF). Ipsen.
^ "Ipsen: A dynamic, fast-growing specialty care powerhouse".
^ "Ipsen | Evaluate".
^ "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 13 December 2022.
^ "Ipsen, le défi américain". Les Echos (in French). 1 October 2015. Retrieved 13 December 2022.
^ France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". www.lechorepublicain.fr. Retrieved 13 December 2022.

[fy2023-1] "FY 2023 results" (PDF). Ipsen.

[2] "Ipsen: A dynamic, fast-growing specialty care powerhouse".

[3] "Ipsen | Evaluate".

[:0-4] "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 13 December 2022.

[5] "Ipsen, le défi américain". Les Echos (in French). 1 October 2015. Retrieved 13 December 2022.

[:1-6] France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". www.lechorepublicain.fr. Retrieved 13 December 2022.

[1]

[2]

[3]

[4]

[5]

[6]